Results from the MagnetisMM-5 study showed that Elrexfio significantly improved progression-free survival, which means ...
SurvivorNet on MSN
CAR T-cell therapy and the hope for a cure in multiple myeloma
CAR T-cell therapy is a treatment that uses a patient’s own T cells, genetically reprograms them in a lab to recognize ...
A new research paper was published in Volume 17 of Oncotarget on April 28, 2026, titled "Targeted therapeutics and U.S. population-level mortality trends in multiple myeloma: A SEER-based analysis ...
A healthcare provider shares her journey with multiple myeloma, discussing the physical, emotional and financial challenges ...
Nearly three years after the FDA approved Pfizer's bispecific antibody Elrexfio as a late-line treatment for patients with ...
CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina ...
SurvivorNet on MSN
CELMoDs: The next-generation drugs that could replace Revlimid in myeloma treatment
Right now, CELMoDs are being studied in patients whose cancer has returned after prior treatment, but their role could expand ...
For more than a year, Diane Hunter, now 72, had been experiencing vague symptoms — pain in her spine and hips, nausea, exhaustion, thirst, and frequent urination. Her primary care physician had ruled ...
Bispecific antibodies are currently approved as late-line therapy, but they are moving up to earlier lines “as they prove ...
CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization ...
Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results